A Loss for Johnson & Johnson: Win for Victims: Jury Verdict in Risperdal Male Breast Trial
Updated February 24, 2015
Well that didn’t take long:
A Philadelphia jury decided the health care giant must pay $2.5 million in damages for failing to warn that its Risperdal antipsychotic could cause gynecomastia, which is abnormal development of breasts in males. The lawsuit was brought by the family of an autistic boy who took the drug in 2002 and later developed size 46 DD breasts, according to a lawyer for the family. Wall Street Journal
A loss for Johnson & Johnson is a win for every victim-but they’re still not awarding victims anywhere near what these cases are worth. Victim’s attorneys better start stepping it up and not accepting these small settlements. Let’s not forget they spent $2.6 billion on advertising in 2013.
Interesting one former FDA commissioner David Kessler testified against Johnson & Johnson while another former FDA commissioner Mark McClellan now sits on Johnson & Johnson’s board. Anyone else see that as a conflict of interest?
February 23, 2015
Fact based evidence over time is the best indicator of the future and let’s hope a jury in Philadelphia subscribes to that logic when deciding if 1. Johnson & Johnson hid Risperdal’s potential trigger to grow breasts? 2. Did Johnson & Johnson adequately disclose the side effect?
Let’s see a judge confirmed Johnson & Johnson destroyed evidence in upcoming mesh trials. Johnson & Johnson may have committed fraud while wrongfully accusing mesh victims of fraud. Johnson & Johnson paid over $5 billion in federal fines in the last few years-those are some pretty sobering facts when it comes to the company.
Well maybe what they didn’t wasn’t all that bad, right?
After a trial lasting almost a month, lawyers for both sides summed up their arguments Friday. On the one side is a young man who developed breasts–size 46DD, according to Bloomberg–while taking J&J’s antipsychotic drug (Risperdal). His attorneys argue that JNJ’s own data shows that the company knew about the risk, but didn’t warn doctors or patients for years. Fierce Pharma
Well surely executives were held accountable for a young man who developed 46DD’s, where 31 children died and another 1,207 were seriously injured, right? I guess if you call paying a $2.2 billion in federal fines and getting promoted from VP of Marketing of Risperdal to President of Janssen maker of Risperdal and then again promoted to CEO of Johnson & Johnson Worldwide well then Alex Gorsky has been punished for his crimes.
His pediatric neurologist testified Monday, saying that sales reps from JNJ’s Janssen unit had dropped off Risperdal samples 20 times between 2002 and 2004, years before the drug’s first pediatric approval. JNJ in 2013 agreed to pay $2.2 billion to settle Department of Justice and state allegations that it marketed Risperdal for off-label uses, including use in children and adolescents. Two other J&J drugs were also involved in the settlement. Fierce Pharma
In my personal experience and 15 years in the industry no rep delivers that much product without it being a directive from the company. And that directive in my experience has always come from the executive level or higher. Again the cycle of encouraging, replicating and rewarding unethical and or illegal behavior or threats of job loss if not compliant with the unethical and or illegal behavior is not an uncommon tactic under The Sociopathic Business Model™.
Let’s all hope the Philadelphia jury will force accountability on Johnson & Johnson’s Janssen maker of Risperdal and it’d be nice if they could go after the ill-gotten gains of the executives that continued to get promoted, Alex Gorsky, Gary Pruden and Bridget Ross.